Murine norovirus (MNoV) is an important model of human norovirus (HNoV) and mucosal 26 virus infection more broadly. Viral receptor utilization is a major determinant of cell 27 tropism, host range, and pathogenesis. The bona fide receptor for HNoV is unknown. 28
can use the either CD300ld or CD300lf as a receptor in vitro. We also showed that 48
CD300lf deficient mice were resistant to oral challenge with a single virus strain. Here we 49 determined that CD300lf is essential for infection of diverse murine norovirus strains in 50 cell lines and in mice with normal immune systems demonstrating it's the primary 51 physiologic receptor for diverse murine norovirus strains independent of infection route. 52
Introduction and MNoV CR7 (Table 1) 21, [39] [40] [41] . An alignment of strains highlights the broad amino acid 140 conservation of the capsid protein, including the CD300lf binding sites, and bile-acid 141 interacting sites described previously ( Fig S1) 13 . Among these strains, there is no 142 variability in the 11 VP1 residues shown to interact with the secondary bile salts 143 glycochenodeoxycholic acid (GCDCA) or lithocholic acid (LCA) 13 . However, there is 144 variation in 4 of the 17 VP1 residues previously shown to interact with CD300lf, 145 suggesting diverse strains may utilize receptors other than CD300lf ( Fig S1) 13 . To test 146 the hypothesis that diverse MNoV strains differentially utilize CD300lf, we first tested 147 whether CD300lf was necessary and sufficient for infection by these strains in vitro. We 148 challenged CD300lf-deficient BV2 microglial cells with six diverse MNoV strains. All 149 strains induced cell death in wild-type BV2 cells but not CD300lf-deficient cells, 150 demonstrating CD300lf is essential for virus induced-lethality in BV2 cells (Fig 2A) . 151
Next, we asked whether CD300ld and CD300lf are sufficient to confer susceptibility to 152 human HeLa cells. Consistent with our prior findings, both CD300ld and CD300lf are To determine whether CD300lf was essential for infection in vivo, we challenged 159
Cd300lf +/and Cd300lf -/littermates with 10 6 PFU PO of either MNoV CW3 , MNoV CR6 , 160
MNoV WU23 , MNoV CR3 , or MNoV CR7 for seven days. These viruses represent each of the 161 five distinct MNoV VP1 phylogenetic clusters described previously 39 . MNoV CW3 causes 162 acute systemic infection that is cleared by 10-14 days post-infection (dpi), while 163
MNoV CR6 , MNoV CR3 , and MNoV CR7 cause persistent infection 21 . The in vivo 164 characteristics of MNoV WU23 are uncharacterized 21 . Consistent with prior studies, we 165 observed differential tissue tropism associated with different MNoV strains 21 . In control 166 mice, viral genomes for all tested MNoV strains were shed in the feces of some mice 167 with the exception of MNoV CW3 (Fig 2C) . All tested MNoV strains were detected in the 168 MLN ( Fig 2D) . All strains were detectable albeit at varying levels in the ileum and colon. 169
Interestingly, only MNoV strains MNoV CW3 and MNoV WU23 were detectable in the 170 spleen. MNoV CR6 , MNoV CR3 , and MNoV CR7 , which are known to establish chronic 171 infection in immunocompetent mice did not have detectable viral genomes in the 172 spleen. MNoV genomes were not detected in any tissue (MLN, spleen, ileum, colon, or 9 feces) of any Cd300lf-deficient mice challenged with any of the five MNoV strains (Fig 174 2C-G). To determine whether there was MNoV infection below the limit of detection, we 175 collected feces from Cd300lf +/or Cd300lf -/mice challenged with MNoV CR6 seven days 176 prior, and then gavaged the feces into Stat1 -/recipient mice which lack innate immunity 177 and are exquisitely sensitive to MNoV infection 14, 15 . Seven days after fecal gavage we 178 detected MNoV CR6 in Stat1 -/mice challenged with feces from Cd300lf +/mice but not 179 from Cd300lf -/mice ( Fig 2H) . These results suggest CD300lf is critical for infection by 180 multiple MNoV strains in immunocompetent mice in vivo. 181
To further determine whether CD300ld or an alternative receptor was sufficient 182 for MNoV infection below our limit of detection, we assessed the humoral immune 183 response against MNoV CW3 at 14 days dpi, a time point after viral clearance by the 184 adaptive immune system. A 1:10 dilution of sera from Cd300lf +/mice that cleared 185
MNoV CW3 infection neutralized MNoV CW3 in vitro as measured by BV2 cell viability (Fig  186   3A ). The IC50 from Cd300lf +/mice was approximately 1:80 in contrast to sera from 187
Cd300lf -/mice which did not reach an IC50 ( Fig 3B) . To determine whether MNoV CW3 188 elicited a non-neutralizing humoral response in Cd300lf -/mice, we measured anti-189
MNoV IgG and IgM in the sera. Cd300lf +/mice had a significantly higher anti-MNoV 190
IgG and IgM response consistent with resistance of Cd300lf -/mice to MNoV CW3 191 infection ( Fig 3C-D) . 192
Next, we asked whether CD300lf was essential for fecal-oral transmission of 193
Stat1 -/background with 10 6 PFU MNoV CW3 PO, which is greater than 1000-fold above 195 the lethal dose 15 . All Cd300lf +/+ Stat1 -/succumbed to lethal infection by five dpi (Fig 4A) .
10
Cd300lf +/-Stat1 -/similarly all died but with a one-day delay in death suggesting a 197 modest CD300lf gene dosage effect on MNoV pathogenesis. In contrast, all ten 198
Cd300lf -/-Stat1 -/mice survived until at least 21 dpi without overt clinical manifestations 199 ( Fig 4A) . 200
Given the distinct target cell types, tissue tropism, and pathogenesis between 201
MNoV strains, we next tested whether Cd300lf -/-Stat1 -/mice were susceptible to 202 MNoV CR6 infection. In contrast to MNoV CW3 , MNoV CR6 is not lethal in Stat1 -/mice 203 although the virus replicates to higher titers and can spread to extra-intestinal tissues 14 . 204
All Cd300lf +/+ Stat1 -/and Cd300lf +/-Stat1 -/mice challenged with 10 6 PFU PO MNoV CR6 205 survived the seven-day infection. Viral genomes were detected in the feces, MLN, 206 spleen, ileum, and colon ( Fig 4B-F ). There was a modest CD300lf gene dosage effect 207 in the spleen (p<0.05) among Cd300lf +/+ and Cd300lf +/mice, but this was not 208 statistically significant in the MLN, ileum, colon, or feces ( Fig 4C-F ). Relative to Stat1 +/+ 209 mice, viral genome copies were elevated and extra-intestinal spread to the spleen was 210 observed consistent with prior findings (Fig 2C-G) . Importantly, Cd300lf -/-Stat1 -/mice 211 were resistant to MNoV CR6 in all tissues examined. Two Cd300lf -/-Stat1 -/mice had 212 detectable viral genomes in the MLN but not in other tissues ( Fig 4C) . A third mouse 213 had detectable low-level viral RNA in the colon but not in any other tissue, possibly 214 reflective of input virus or a false positive ( Fig 4F) . 215
The natural defenses of the gastrointestinal mucosa represent a bottleneck to 216 viral infection. To test whether CD300lf was essential for parenteral infection routes, we 217 bypassed the gastrointestinal tract by administering 10 7 PFU MNoV CW3 intraperitoneally 218 (IP) to Cd300lf -/-Stat1 -/mice. All Cd300lf +/+ Stat1 -/and Cd300lf +/-Stat1 -/mice died by 219 five or six dpi, respectively ( Fig 5A) . Two of nine Cd300lf -/-Stat1 -/mice died at 10 and 220 14 dpi with the remaining mice surviving at least 21 days. The two Cd300lf -/-Stat1 -/-221 mouse deaths were observed in independent experiments. Virological data was not 222 available from these animals; therefore, whether MNoV CW3 contributed to the death of 223
Next, we challenged mice with 10 7 PFU MNoV CR6 IP. In contrast to the lower-225 dose MNoV CR6 administered PO, 77% (7/9) of Cd300lf +/+ Stat1 -/mice and 66% (2/3) 226 Fig 5B) . All six Cd300lf -/-Stat1 -/mice survived IP infection 227 with 10 7 MNoV CR6 until sacrifice at seven dpi. Interestingly, MNoV CR6 genomes were 228 detected in the MLN, spleen, ileum, and colon of Cd300lf -/-Stat1 -/mice ( Fig 5C) . 229
MNoV CR6 from Cd300lf -/-Stat1 -/mice infected with 10 7 PFU MNoV CR6 IP was Sanger 230 sequenced, revealing a single nucleotide change (T6595A) resulting in a phenylalanine 231 to isoleucine mutation at position 514 (F514I) in the P1 domain of VP1 (Supplemental 232   Table 1 ). This mutation was detected in the spleen, ileum, and colon from two different 233 mice. Thus, while CD300lf is essential for MNoV infection by oral inoculation in 234 immunocompetent hosts, CD300lf-independent replication of MNoV may occur under 235 high-dose IP challenge in Stat1 -/mice. 236
To determine whether the F514I variant observed enabled CD300lf-independent 237 infection, we generated an infectious molecular clone containing this mutation on the 238 MNoV CR6 background (MNoV F514I ). Similar to MNoV CR6 , MNoV F514I was cytotoxic to WT 239 BV2 cells but did not affect cell viability in Cd300lf-deficient BV2 cells, demonstrating 240 this mutation did not enable alternative receptor utilization in BV2 cells ( Fig 6A) . We 241 then asked whether MNoV F514I could preferentially utilize CD300ld relative to CD300lf 12 when ectopically expressed in HeLa cells. MNoV F514I and MNoV CR6 were both able to 243 utilize CD300ld and CD300lf at similar ratios when overexpressed suggesting this 244 mutation does not enhance CD300ld utilization in vitro ( Fig 6B) . Next, we thermally 245 stressed MNoV CR6 , MNoV F514I , MNoV CW3 to probe differences in virion stability as 246 mutations that confer heat resistance were recently demonstrated to alter the VP1 247 conformation and thus may affect receptor utilization 42 . MNoV F514I and MNoV CR6 had 248 similar thermal stability ( Fig 6C) . Interestingly, this was increased relative to MNoV CW3 249 ( Fig 6C) . To investigate whether MNoV F514I altered receptor utilization in vivo, we 250 challenged Cd300lf +/or Cd300lf -/mice with 10 6 PFU MNoV F514I PO. MNoV F514I readily 251
infected Cd300lf +/mice and maintained similar tissue tropism as the parental MNoV CR6 252 ( Fig 6D-G) . Also similar to MNoV CR6 , MNoV F514I genomes were not detectable in the 253 MLN, spleen, ileum, colon, or feces of CD300lf -/mice suggesting MNoV F514I is not 254 sufficient to alter receptor utilization in immunocompetent mice when administered PO 255 ( Fig 6D-H) . 256
Next, given the structural and genetic similarity between MNoV and HNoV, we 257 tested whether human CD300lf (huCD300lf) is a receptor for HNoV. First, we assessed 258 the ability of huCD300lf to prevent binding of recombinant HNoV virus-like particles 259 (VLPs) to HBGAs in pig gastric mucin. To increase the avidity of the potential CD300lf 260 and VLP interaction, we generated Fc-fusion proteins with the either huCD300lf or 261 human CD300ld (huCD300ld) ectodomains. We recently demonstrated that an Fc-262 fusion protein of mouse CD300lf has substantially increased binding and neutralizing 263 ability on MNoV 13 . We incubated HNoV VLPs with 10 µg/ml of either Fc-huCD300lf, Fc-264 huCD300ld, or a buffer-only control and measured HBGA-bound VLPs by ELISAs. 265
Neither Fc-huCD300lf or Fc-huCD300ld inhibited binding of GI.1 Norwalk, GI.3 Desert 266 Shield Virus, GII.4 1997, or GII.4 2012 VLPs to HBGAs ( Fig 7A) 43, 44 . Next, we asked 267 whether potential HNoV interactions with huCD300lf were necessary for infection of 268 human intestinal enteroids (HIEs). Differentiated monolayers of HIEs were incubated 269 with polyclonal anti-huCD300lf or an IgG1 control and then challenged with HNoV GII.4 270 from stool filtrate. Anti-huCD300lf had no effect on HNoV genome replication at 24 hpi 271 relative to the isotype control ( Fig 7B) . Finally, we asked whether Fc-huCD300lf could 272 neutralize HNoV GII.4. Virus was pre-incubated with up to 50 µg/ml of Fc-huCD300lf 273 and then used to infect HIEs. Fc-huCD300lf did not affect viral genome replication 274 relative to a control protein ( Fig 7C) . Together these data indicate that huCD300lf is not 275 a receptor for HNoV. 276
277
Discussion 278
Here we demonstrate that CD300lf, and not CD300ld, is the primary physiologic receptor 279 for diverse MNoV strains in vivo. We demonstrated that CD300lf is essential for 280 detectable viral infection at multiple time points with diverse MNoV strains as measured 281 by plaque assay, qPCR, and serologic response. Interestingly, both CD300ld and 282
CD300lf are sufficient to mediate MNoV entry when ectopically expressed in vitro yet 283
CD300ld is not sufficient for oral or parenteral transmission in immunocompetent mice. 284
Several possibilities may explain this discordance. First, CD300ld receptor utilization has 285 only been described when overexpressed at supraphysiologic levels 15, 16 . Similarly the 286 soluble recombinant ectodomain of CD300lf can neutralize MNoV infection in contrast to 287 that of CD300ld 15 . This raises the possibility that CD300ld utilization by MNoV is inefficient 288 relative to CD300lf and that our overexpression assays are not sufficiently sensitive to 289 quantify differences in receptor utilization efficiency. A similar phenomenon has been 290 described with HIV-1, which can engage co-receptors other than CCR5 and CXCR4 when 291 overexpressed in cell lines, but not under physiologically relevant conditions 45, 46 . Second, 292 whether it has physiologic relevance. One possibility is that MNoV F514I enables the virus 305 to better utilize CD300ld, or an unknown alternative receptor in vivo, but only in a Stat1-306 deficient background. Defects in innate immunity may enable broader cell tropism due to 307 removal of post-entry viral restriction, thus permitting CD300lf-independent replication in 308 vivo. The molecular consequences of F514I are intriguing in that this mutation is on the 309 opposite side of the P domain from the receptor binding site, suggesting an allosteric 310 mechanism of receptor regulation. One such mechanism could be altering the 311 "breathability" of the P domain, which is connected to the capsid shell by a flexible 312 linker 12,48 . Bile salts both increase MNoV-receptor binding and induce collapse of the P 313 domain onto the shell 12 . Whether F514I has a similar effect remains an important future 314 direction. 315
The physiologic function of CD300lf is as a cell death sensor and 316 immunoregulatory protein 25 . Interestingly, the CD300 locus is under positive selection and 317
there are a number of CD300lf polymorphisms in laboratory and wild mouse strains that 318 may affect CD300lf expression or conformation and thus may regulate susceptibility to 319
MNoV 49 . This raises the intriguing hypothesis of a molecular arms race between MNoV 320 and mice over evolutionary time which may have contributed to the relative avirulence of 321
MNoV in immunocompetent mice. 322
Finally, these data have several important implications for our understanding of 323
HNoV, the entry mechanisms of which remain to be defined. Given the structural similarity 324 between MNoV and HNoV as well as mouse and human CD300lf, we hypothesized that 325 human CD300lf might be a functional receptor for HNoV. However, via multiple 326 orthogonal approaches we demonstrated that human CD300lf is not a functional receptor 327
for several GI and GII HNoVs. This further raises the question as to the identity of the 328 HNoV receptor and whether or not it is structurally related to CD300lf. This remains an 329 important area of future investigation that would significantly enhance our understanding 330 of HNoV pathogenesis and facilitate novel prophylactic and therapeutic approaches. 331 332 333
Materials and Methods 334

Mouse strains 335
All mouse strains used in this experiment were from a C57BL/6J background (Jackson 336
Laboratories, Bar Harbor, ME) and bred in-house. Generation of B6.CD300lf em1Cbwi /J 337
H.W. Virgin) were previously described 15,50 . These mice were housed in a MNoV-free 339 facility at Yale University School of Medicine. All experiments used littermate controls, 340
were gender-balanced, and done at least two independent times. Mice were used for 341 infections between 6-10 weeks of age. Genotyping of mice was done by real time PCR 342 as described previously 15 . 343 344
Ethics statement 345
The care and use of the animals were approved by and in agreement with the Yale Animal 346
Resource Center and Institutional Animal Care and Use Committee (#2018-21098) 347 according to standards in the Animal Welfare Act. 348 349
Viral stocks 350
MNoV CW3 (Gen bank accession EF014462.1), MNoV CR6 (accession JQ237823), and 351
MNoV MNV3 (accession JQ658375.1) were generated from infectious molecular clones. with MNoV CW3 at a MOI 5 for flow cytometry experiments and a MOI 0.05 for plaque 392 assays. Human enteroids were inoculated with HNoV GII.4 from stool filtrate as described 393 previously 8 . Tranfected 293T cells were challenged with HNoV GII.6 from stool filtrate as 394 described below. The HNoV GII.6 stool filtrate was determined to be infectious using 395 BJAB cells as described previously 9 . 396 397
In vitro HNoV infections in HIEs 398
Five-day differentiated jejunal HIE monolayers in 96-well plates were inoculated with 399
HNoV GII.4_Sydney_2012 (2.5x10 5 genome copies/well) from stool filtrate as described 400 with 1% Pen/Strep, and 1% HEPES 38 . Tissue homogenates were serially diluted ten-fold. 441
Media was aspirated off the BV2 cells and samples were inoculated to each well and 442 gently rocked for 1 hour. Inoculum was removed and 2 mL of overlay media (MEM 443 containing 1% methylcellulose, 10% FBS, 1% GlutaMAX (Gibco), 1% HEPES, and 1% 444 pen/strep) was added to each well. Inoculated plates were incubated for 48 hours at 37°C 445 and 5% CO2 prior to plaque visualization with crystal violet (0.2% crystal violet in 20% 446 ethanol) as described previously 37 . Plaque assay from cell culture was performed by 447 freeze/thawing infected samples at 0, 12, and 24 hpi followed by serial dilutions as 448 described above 15, 37 . 449 450
Quantitative PCR 451
MNoV genome copies in fecal pellets and tissues were determined as previously 452 
Neutralization Assay 500
Cd300lf -/or Cd300lf +/mice were infected PO with 10 6 PFU MNoV CW3 and terminally bled 501 via cardiac puncture at 14 dpi. Whole blood was collected in an EDTA Microtainer tube 502 (BD) and pelleted at 5800 x g for 10 min. Plasma was removed and stored at 4°C until 503 use. BV2 cells were seeded at 20,000 cells in 50µL per well in a 96-cell plate and 504 incubated at 37°C. Sera were serially diluted in D10 with an initial dilution 1:9 and with 505 five subsequent three-fold dilutions. Then, 10 5 PFU of MNoV CW3 was added to each well 506 and mixtures were gently rocked for 30 min at room temperature (RT) and then added to 507 BV2 cells. After 48 hours, 25µL of CellTiter-Glo was added to each well and luminescence 508 was detected on a luminometer. Experiments were performed in duplicate with at least 509 three independent replicates. 510 511
MNoV-specific ELISA 512
In a 96-well MaxiSorp plate, 100µL of two-fold serially diluted IgG (starting at 12.5ng/mL) 513
and IgM (starting at 25ng/mL) was used as standard controls and MNoV CR6 was used to 514 coat the plate overnight at 4°C. The plate was then washed three times with 300µL wash 515 buffer (0.05% Tween-20 in PBS) and then blocked with 100µL of blocking solution (1% 516 BSA in PBS) for 1 hour at RT. After washing 3 times, 50µL of sample at appropriate 517 dilutions in blocking solution was added to each well and incubated for 2 hours at RT. The 518 plate was further washed three times and 50µL of anti-mouse IgG-HRP (A3673, Sigma-519 Aldrich) or anti-mouse IgM-HRP (A8786, Sigma-Aldrich) diluted in blocking solution was 520 added to each well, then incubated for 2 hours at RT. Wells were washed three times, 521 and then 40µL of ELISA TMB substrate solution (eBioscience, San Diego, CA) was added 522 to each. Plates were incubated for 20 min, then 20µL of stop solution (2N H2SO4) added 523 and OD determined at 450 nm and reference wavelength 570 nm. 524
525
ELISA for HuNoV VLPs binding to PGM 526
Pig gastric mucin (Sigma-Aldrich) was immobilized at 10 µg/ml in PBS on 96-well-plate 527 at 4°C overnight. Wells were washed with PBS-0.05% Tween 20 (PBS-T) three times. 528
After blocking with 5% non-fat milk at RT for 1 hour, plates were washed once with PBS-529 T. Fc-huCD300 proteins (10 µg/ml) were mixed with purified HuNoV VLPs at indicated 530 concentrations and then added and incubated for 1 hour at RT. The wells were washed 531 three times with PBS-T followed by addition of rabbit anti-VP1 sera diluted in PBS 532
(1:2000). Wells were incubated at RT for 1 hour, followed by washing with PBS-T three 533 times as described previously 44 . Secondary goat anti-rabbit-HRP diluted in PBS were 534 added and incubated for 1 hour. After five washes, TMB substrate was added, and 2M 535 H2SO4 was applied to stop the reaction. Absorbance at 450 nm was measured. Figure S1. Tree and VP1 alignment showing CD300 interacting sites. VP1 is the major structural protein of MNoV and is comprised of a shell and protruding domain. The complete VP1 sequence of MNoV strains CW3, CR6, CR3, CR7, WU23, MNV3, and S99 were aligned. The VP1 shell domain comprises the core of the virion and is sufficient for virion assembly. The protruding domain mediates binding to CD300lf and bile salts and is comprised of discontinuous P1 and P2 subdomains. The CD300lf and secondary bile acid (GCDCA) binding sites are highlighted as is the F514I mutation which emerged during infection of Cd300lf-/-Stat1-/-mice13. Secondary structures labeled as alpha-helices (α), 310-helices (η), and beta-strands (β). The number following the annotation is the numerical order of that secondary structure. Helices are displayed as squiggles and strands are represented by a forward moving arrow under the annotation. TT = strict β-turns and TTT = strict α turns.
